Uma Sinha
Chief Tech/Sci/R&D Officer presso EIDOS THERAPEUTICS, INC.
Patrimonio netto: 49 200 $ in data 31/03/2024
Profilo
Attualmente, Uma Sinha occupa la posizione di direttore scientifico di BridgeBio Pharma, Inc. e direttore scientifico di Eidos Therapeutics, Inc. (una filiale di BridgeBio Pharma, Inc.). La dott.ssa Sinha ha precedentemente ricoperto la posizione di responsabile scientifico della Global Blood Therapeutics, Inc., Principal presso COR Therapeutics, Inc., Senior Director-Cardiovascular presso Millennium Pharmaceuticals, Inc., Principal presso Genencor International, Inc. e Vice President & Head-Biology presso Portola Pharmaceuticals, Inc. Ha conseguito un dottorato presso l'Università della Georgia e una laurea presso il Presidency College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
PROKIDNEY CORP. CLASS A
0.05% | 29/06/2023 | 30 000 ( 0.05% ) | 49 200 $ | 31/03/2024 |
Posizioni attive di Uma Sinha
Società | Posizione | Inizio |
---|---|---|
EIDOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2016 |
BRIDGEBIO PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/04/2016 |
PROKIDNEY CORP. | Director/Board Member | - |
Precedenti posizioni note di Uma Sinha
Società | Posizione | Fine |
---|---|---|
GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2015 |
PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2012 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | 01/01/2002 |
SOCL CAPI | Director/Board Member | - |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Corporate Officer/Principal | - |
Formazione di Uma Sinha
University of Georgia | Doctorate Degree |
Presidency College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
BRIDGEBIO PHARMA, INC. | Health Technology |
PROKIDNEY CORP. | Health Technology |
Aziende private | 7 |
---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Social Capital Suvretta Holdings Corp. III
Social Capital Suvretta Holdings Corp. III Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. III is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Henderson, NV. | Finance |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Uma Sinha